Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. (NYSE: STVN) is a global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences companies. Its news flow, as reflected in recent press releases and SEC filings, centers on financial performance, capacity expansion, financing arrangements, and participation in healthcare investor conferences.
Investors following STVN news will find regular quarterly earnings announcements detailing revenue trends, segment performance for the Biopharmaceutical and Diagnostic Solutions and Engineering segments, margin evolution, and the growing contribution of high-value solutions such as high-performance Nexa® syringes and EZ-fill® vials and cartridges. These updates often include discussion of non-GAAP measures, capital expenditures, and liquidity.
News coverage also highlights strategic investments and footprint optimization, including expansions at manufacturing facilities in Cisterna di Latina and Fishers to increase pre-filled syringe and ready-to-use cartridge capacity, and enhancements at the Bad Oeynhausen, Germany, site for drug delivery system production. Financing news, such as the €200 million agreements with BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM, provides additional context on how Stevanato Group funds these projects.
In addition, Stevanato Group frequently announces its participation in major healthcare and investor conferences in locations such as New York, London, Las Vegas, Chicago, and Vienna. These events offer further insight into management’s views on market dynamics, high-value solutions, and long-term strategy.
By monitoring this page, readers can track Stevanato Group’s latest earnings releases, operational updates on capacity expansion and optimization plans, financing developments, and investor relations activities, all drawn from company-issued news and regulatory communications.
Stevanato Group (NYSE: STVN) reported a strong second quarter of 2022, achieving a 15% revenue growth to €234.2 million. The company raised its full-year guidance, projecting revenue between €955 million and €965 million. Adjusted diluted EPS was €0.12, with a 31.8% gross profit margin. The backlog rose 37% to approximately €1.01 billion, driven by increased demand in Biopharmaceutical and Diagnostic Solutions. Despite lower COVID-19-related revenue, the Core business showed robust demand.
Stevanato Group (NYSE: STVN) will release its second quarter 2022 financial results on August 4, 2022, at 6:30 a.m. EST. A conference call and webcast will follow at 8:30 a.m. EST to discuss the results, accompanied by a slide presentation available on their Investor Relations webpage. Interested participants can pre-register for immediate access. The company provides drug containment, delivery, and diagnostic solutions for the pharmaceutical and biotechnology sectors, emphasizing its engineering and innovation capabilities.
Summary not available.
Stevanato Group S.p.A. (NYSE: STVN) announced that all resolutions proposed at its Annual General Meeting (AGM) on
Stevanato Group (NYSE: STVN) announced its participation in two upcoming investor conferences. On
Stevanato Group (NYSE: STVN) has announced the acquisition of a 65,000-square-meter industrial complex in Cisterna di Latina, Italy. This facility aims to enhance the company’s production capabilities in response to rising demand for its drug containment solutions. The new site will employ approximately 190 people and partially utilize renewable energy sources. Operations are set to commence in 2023, boosting the production of standard and EZ-fill® solutions. CEO Franco Moro emphasizes the strategic expansion in a major pharmaceutical hub to better serve customer needs.
Stevanato Group (NYSE: STVN) reported a 10% revenue increase in Q1 2022, totaling €212.1 million. Diluted EPS stood at €0.10, with adjusted diluted EPS at €0.11. The backlog surged 49% to €992.2 million, driven by a 29% rise in high-value solutions. Gross profit margin improved to 31.8%, although production faced temporary slowdowns due to Covid-related absenteeism. The company maintains its fiscal 2022 guidance, projecting revenue between €935 million and €945 million and adjusted diluted EPS between €0.49 and €0.51.
Stevanato Group, a global provider of drug containment and delivery solutions, announced its 2022 Annual General Meeting (AGM) will take place virtually on June 1, 2022, at 4:00 p.m. (CEST). Shareholders can access the meeting agenda, explanatory materials, and voting instructions on the company's investor relations website. Hard copies of the audited financial statements can be requested via email. The press release emphasizes the company's commitment to shareholder engagement and transparency.
Stevanato Group (NYSE: STVN) has entered an exclusive agreement with Owen Mumford to manufacture the Aidaptus® auto-injector. This partnership allows Stevanato to provide engineering and manufacturing support to biopharma companies for drug delivery. Aidaptus® is a flexible, single-use device compatible with multiple syringe sizes and drug viscosities. The collaboration aims to enhance device production efficiency and streamline market access. Stevanato will showcase Aidaptus® at Pharmapack Europe on May 18-19, highlighting its integrated manufacturing capabilities.
Stevanato Group (NYSE: STVN) will release its financial results for Q1 2022 on May 10, 2022, at 6:30 a.m. ET. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can preregister for the call or access it via a live broadcast. Additionally, a replay of the call will be available through May 24, 2022. Founded in 1949, Stevanato Group offers comprehensive solutions for the pharmaceutical, biotechnology, and life sciences industries, focusing on drug containment, delivery, and diagnostics.